Monoclonal antibodies penetrate bulky tumors poorly after intravenous administration, in part because of specific binding to the target antigen. Experiments presented here demonstrate an analogous phenomenon in micrometastases; poor antibody penetration, attributable to a "binding-site barrier" phenomenon, can be seen in guinea pig micrometastases as small as 300 ,um in diameter. Increasing the dose of antibody can partially overcome this limitation, but at a cost in specificity. Six and 72 hr after injection, animals were sacrificed by CO2 inhalation. Organs were rapidly removed and weighed, and tissue radioactivity was determined. Lung tissues with metastases were frozen immediately in OCT compound (Tissue-Tek, Miles) and then processed for autoradiography and immunostaining. For high-dose experiments, 1000 ,ug of unlabeled D3 was added to 30 ,ug of labeled D3. Autoradiography and Immunostaining. Serial 20-,um sections were cut from the frozen lung tissues. For autoradiography, sections were placed on SB-5 film (Eastman Kodak) and exposed for 1-4 days. When 125I-labeled BL3 was coinjected with I311-labeled D3, images of the latter were obtained shortly after sacrifice, images of the former after eight 131I half-lives.
When monoclonal antibodies (mAbs) are administered i.v. to detect or treat a solid tumor, they generally distribute nonuniformly in the mass (1) (2) (3) (4) (5) (6) (7) (8) . A number of possible reasons, reflecting the heterogeneity seen in almost all characteristics of cancer (9) (10) (11) , have been suggested: heterogeneous antigen (Ag) expression within the tumor; heterogeneous blood supply; elevated interstitial pressure; and mechanical barrierse.g., tight junctions between cells (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) .
Mathematical analysis led to another suggestion. According to the binding-site barrier hypothesis (19) (20) (21) (22) (23) , the very fact of successful antibody (Ab) binding to target Ag (or binding followed by metabolism) can retard deep penetration into a tumor. That is, Ab molecules leaving the capillaries can be sequestered by Ag and prevented from diffusing or being carried by convection to more distant Ag sites in the tumor. Lower Ab dose, higher binding affinity, and higher Ag density were all predicted to exacerbate the problem (19) (20) (21) (22) (23) . In previous studies, we obtained direct experimental evidence of a binding site barrier phenomenon in intradermally implanted Line 10 (L10) carcinoma of guinea pigs (5) , and similar results have been obtained in other systems (6, 7) . In the present experiments, we ask whether micrometastases are subject to the same limitation of access and, if so, whether anything can be done about it.
MATERIALS AND METHODS
Experimental Lung Metastases. L10 is a chemically induced guinea pig carcinoma of bile duct origin (24, 25 (26) . The affinity constant and maximal binding of D3 were estimated as 109 M-1 and 3.55 x 105 molecules per cell, respectively (8) . BL3, a murine IgG1 directed against a human B-cell lymphoma idiotope, was used as an isotype-matched control (27) .
Radioiodination and Immunoreactivity. mAbs were radioiodinated with chloramine T (28). Labeled Ab was separated from free iodine on a PD-10 column (Pharmacia LKB) and, when necessary, affinity purified on glutaraldehyde-fixed L10 cells (8) Autoradiography and Immunostaining. Serial 20-,um sections were cut from the frozen lung tissues. For autoradiography, sections were placed on SB-5 film (Eastman Kodak) and exposed for 1-4 days. When 125I-labeled BL3 was coinjected with I311-labeled D3, images of the latter were obtained shortly after sacrifice, images of the former after eight 131I half-lives.
The avidin-biotin peroxidase complex (ABC) method (29) was used to compare Ab and Ag distribution. Briefly, tissue sections were acetone-fixed for 10 min and incubated with blocking serum for 20 min. To assess Ag expression, sections were incubated with D3 Ab (20 ,ug/ml) for 1 hr at room temperature, biotinylated horse anti-mouse IgG for 45 min, ABC for three 30-min periods, and diaminobenzidine (Vector Laboratories). When injected D3 was assessed, incubation with D3 was omitted. Some sections were also stained for blood vessels by use of polyclonal rabbit anti-factor VIII and an alkaline phosphatase substrate, Vector Red (30) .
RESULTS AND DISCUSSION
In this study, we have assessed the distribution of i.v. administered mAbs in experimental guinea pig lung micrometastases. Two weeks after i.v. injection of L10 cells, multiple metastases 100-1000 ,um in diameter could be seen in the lungs of all animals. This model (metastasis of guinea pig cancer in guinea pigs) is in many ways more relevant to the Abbreviations: Ab, antibody; mAb, monoclonal Ab; Ag, antigen. tPresent address: Department of Nuclear Medicine, Kyoto University Hospital, Kyoto 606-01, Japan. §Present address: Takeda Inc., Yodogawa-ku, Osaka 532, Japan. ITo whom reprint requests should be addressed.
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Pharmacokinetics. Table 1 shows basic pharmacokinetic data for 1311-labeled D3. As expected, the distribution (expressed as % injected dose/g) to organs other than lung appeared essentially independent of dose. Because micrometastases were distributed diffusely throughout the lungs, we could not measure radioactivity in them without including normal lung tissue. At 6 hr, D3 uptake in lung (including metastases) appeared to be independent of dose. At 72 hr, however, when radioactivity had largely cleared from normal lung, the uptake was greater at the low dose (P < 0.001, unpaired two-tail t test), as would be expected if Ag binding sites were becoming saturated. As also expected with Ag saturation, lung/blood ratios and localization indices were greater at the low dose than at the high dose.
Microscopic Distribution of Bindable Ab (D3). To test the binding-site barrier hypothesis, one must determine the histological distribution of four different entities: the injected mAb, a nonbindable control immunoglobulin, the Ag, and blood vessels. Fig. la shows D3 Ag (dark brown) expressed quite uniformly in metastatic nodules. In contrast, Fig. lb shows injected D3 Ab (dark brown) at a dose of 30 ,ug localized after 6 hr in the peripheral one to two cell layers of the nodule and near blood vessels (stained red for factor VIII) at its center. Fig. 1 shows poor penetration of Ab into the substance of micrometastases, as reported for bulky tumors (1) (2) (3) (4) (5) (6) (7) (8) 13) , and also for spheroids (31, 32) . However, these findings did not suffice to identify the mechanism. Possibilities included (i) a mechanical barrier-e.g., tight junctions between cells; (ii) rapid, nonspecific metabolism of Ab molecules as they enter the metastases; and (iii) a binding-site barrier phenomenon, for which Weinstein and coworkers (19) (20) (21) (22) (23) have predicted severely limited penetration even over distances of a few hundred micrometers.
The arrows in Fig. 2 a and b indicate poor penetration of low-dose D3 Ab into a neovascularized (33, 34) metastasis about 700 ,Am in diameter. Also seen are smaller, apparently nonvascular nodules with Ab only at the periphery. Ab distribution 72 hr after injection (Fig. 2 c and d) was too faint for convincing photographic reproduction, but, when viewed in the microscope, it was clearly heterogeneous within the nodules.
High-dose D3 appeared to have penetrated more deeply (two to six cell layers from the nodule margin or intranodular vessels) after 6 hr than had low-dose D3 (Fig. 2 e and f) . However, appearances may be deceptive in this case. The 34-fold higher dose would be expected to achieve a given intensity of staining at greater depth in the nodule, even if the penetration process were simply proportional to concentration gradient (i.e., even in the absence of Ag saturation). By 72 hr ( Fig. 2 g and h) , Ab staining was essentially identical to that of Ag in most nodules.
Autoradiography reinforced the immunohistochemical findings of inhomogeneity. It showed poor penetration of low-dose 131I-D3 at 6 hr after injection (Fig. 3 a and b ) and more diffuse but still somewhat heterogeneous localization at 72 hr ( Fig. 3  c and d) . The findings for high-dose D3 at 6 hr were similar (Fig. 3 e andf) , consistent with the hypothesis that Ab had not saturated very much of the Ag at either dose. In contrast, Fig.  3 somewhat greater percentage (25%) of nodules appearing homogeneously stained at the high dose may have related to nodules cut off-center, given the thicker rims of Ab staining seen. The difference between low-dose and high-dose autoradiograms at 72 hr ( Fig. 3 d and h) The present studies were done with radiolabeled mAbs, but the same principles of microscopic pharmacology apply to other antibody conjugates (37) (38) (39) and to a variety of biological ligands. They are pertinent, for example, to therapy with cytokines, whether administered exogenously or secreted in vivo by genetically modified cells.
